kootpenne schreef op 19 februari 2017 16:25:
[...]
Dit haal ik uit het financial report 2016 op de website van MDX:
Revenues
Total company revenues for the first six months ended June 30, 2016, increased 65% to $12.9 million, compared to total revenues of $7.9 million for the prior year. ConfirmMDx for Prostate Cancer accounted for 83% of the Company’s revenue in H1 2016, compared to 88% in H1 2015. The growth in Q2 2016 revenues compared to the prior period was principally driven by increased sales of ConfirmMDx as well as royalty and milestone payments from Exact Sciences.
In Q3 nieuwe mijlpaalbetalingen van exact sciences? Lijkt me eerder recurrente betalingen dan.
MDxHealth – Annual Report – 2015 Page 68
With the launch of licensee Exact Sciences’ FDA-approved Cologuard test, MDxHealth expects to recognize a milestone fee and deferred license fees in excess of $0.5 million in the near term, and is eligible to receive minimum annual maintenance fees of $100,000 per year, sales milestones of $300,000 after Cologuard attains net sales of $10 million, $750,000 after Cologuard attains net sales of $50 million, and $1 million after Cologuard attains net sales of $50 million in a single calendar year, as well as running royalties in the mid-single digit range. The license agreement is expected to remain in effect until the last of the licensed patents expires in 2028.